Lexeo Therapeutics Future Growth
Future criteria checks 2/6
Lexeo Therapeutics's earnings are forecast to decline at 4.4% per annum while its annual revenue is expected to grow at 80.5% per year. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be -46.7% in 3 years.
Key information
-4.4%
Earnings growth rate
14.3%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 80.5% |
| Future return on equity | -46.7% |
| Analyst coverage | Good |
| Last updated | 17 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18
Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -86 | -90 | -87 | 5 |
| 12/31/2025 | 1 | -95 | -91 | -90 | 7 |
| 12/31/2024 | N/A | -85 | -81 | -80 | 7 |
| 6/30/2024 | N/A | -77 | -63 | -63 | N/A |
| 3/31/2024 | N/A | -69 | -56 | -56 | N/A |
| 12/31/2023 | N/A | -66 | -60 | -59 | N/A |
| 9/30/2023 | N/A | -67 | -62 | -62 | N/A |
| 6/30/2023 | 1 | -64 | -61 | -60 | N/A |
| 3/31/2023 | 1 | -64 | -61 | -60 | N/A |
| 12/31/2022 | 1 | -59 | -55 | -55 | N/A |
| 12/31/2021 | 2 | -51 | -44 | -44 | N/A |
| 12/31/2020 | 1 | -5 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXEO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LXEO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LXEO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LXEO's revenue (80.5% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: LXEO's revenue (80.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXEO is forecast to be unprofitable in 3 years.